Biomarkers and diagnosis

Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis

George T, Staron A, Burks EJ, Szalat RE, Sanchorawala V

British Journal of Haematology208(6):2252-2255DOI: Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosisPubMed: Cyclin D1 immunostaining as a diagnostic surrogate for the t(11;14) translocation in AL amyloidosis

Role of minimal residual disease assessment in multiple myeloma

Szalat R, Anderson K, Munshi N

Haematologica109(7):2049-2059DOI: Role of minimal residual disease assessment in multiple myelomaPubMed: Role of minimal residual disease assessment in multiple myeloma

Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis

Acevedo J, Doros G, Szalat R, Sanchorawala V

Clinical Lymphoma Myeloma and Leukemia21(6):425-426DOI: Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL AmyloidosisPubMed: Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Samur MK, Aktas Samur A, Fulciniti M, Szalat R, …, Munshi NC

Journal of Clinical Oncology38(27):3107-3118DOI: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome GroupPubMed: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Walker BA, Mavrommatis K, Wardell CP, …, Szalat R, …, Morgan G

Leukemia33(1):159-170DOI: A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisPubMed: A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Diagnosis of Castleman Disease

Szalat R, Munshi NC

Hematology/Oncology Clinics of North America32(1):53-64DOI: Diagnosis of Castleman DiseasePubMed: Diagnosis of Castleman Disease

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Fulciniti M, Martinez-Lopez J, Senapedis W, …, Szalat R, …, Munshi NC

Blood129(16):2233-2245DOI: Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myelomaPubMed: Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications

Jakubikova J, Cholujova D, Hideshima T, …, Szalat RE, …, Anderson KC

Oncotarget7(47):77326-77341DOI: A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applicationsPubMed: A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications

Physiopathology of necrobiotic xanthogranuloma with monoclonal gammopathy

Szalat R, Pirault J, Fermand J‐, …, Goff WL

Journal of Internal Medicine276(3):269-284DOI: Physiopathology of necrobiotic xanthogranuloma with monoclonal gammopathyPubMed: Physiopathology of necrobiotic xanthogranuloma with monoclonal gammopathy

Performance Evaluation of a Novel Non-Invasive Monitoring Device for At-Home Neutropenia Detection in a Multicenter Cancer Cohort

Srinivasan MD, Sloan JM, Wolf M, Ferri GM, Çetin O, Szalat RE, et al.

Breast Cancer Research and Treatment 215 (1)

The apobec mutational activity in multiple myeloma: from diagnosis to cell lines

Maura F, Petljak M, Minvielle S, Szalat R, Lionetti M, Cifola I, Liang W, et al.

haematologica102(suppl. 3):124-124

IgM Hevylite Assay as a Biomarker of Clinical Outcome in Patients with Anti-MAG Neuropathy: P-457

ARNULF B, BENGOUFA D, LAZARETH A, SZALAT R, MALPHETTES M, et al.

Clinical Lymphoma, Myeloma & Leukemia13:s254-s255